Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Pancreatic Cancer — Nursing Symposium Proceedings

Faculty

Nurse

Caroline Kuhlman

MSN, APRN-BC

Massachusetts General Brigham Cancer Institute, Boston, Massachusetts

Nurse Practitioner, Tucker Gosnell Center for Gastrointestinal Cancers

Faculty

Philip A Philip

MD, PhD

Wayne State University Department of Oncology, Detroit, Michigan

Chair, Hematology and Oncology, Professor of Oncology and Pharmacology, Co-Leader, Pancreatic Cancer Program, Medical Director, Cancer Clinical and Translational Research Office, Chair, GI Cancer, SWOG, Henry Ford Cancer Institute

Nurse

Amanda K Wagner

APRN-CNP, AOCNP

The James Cancer Hospital, The Ohio State University, Columbus, Ohio

GI Malignancies

Moderator

Eileen M O’Reilly

MD

David M Rubenstein Center for Pancreatic Cancer Research, New York, New York

Winthrop Rockefeller Endowed Chair in Medical Oncology, Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers, Co-Director, Medical Initiatives

Memorial Sloan Kettering Cancer Center, New York, New York

Chair, Human Research Protection Program and IRB, Attending Physician, Member

Weill Cornell Medical College, New York, New York

Professor of Medicine

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with pancreatic cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for pancreatic cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
• Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
• Examine available datasets exploring the effect of dose adjustments on the efficacy of chemotherapeutic regimens employed in the management of newly diagnosed metastatic PAD, and consider the potential feasibility of tolerability-guided dosing strategies.
• Recognize FDA-approved treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these strategies.
• Evaluate the mechanism of action of, published research findings with and current clinical role of tumor treating fields for unresectable, locally advanced PAD.
• Recall relevant oncogenic pathways mediating the pathogenesis of PAD, and discern the implications for biomarker analysis and treatment decision-making.
• Appreciate the spectrum and frequency of RAS mutations found in patients with metastatic PAD, and develop an understanding of available and emerging data with and ongoing research studies of novel agents designed to exploit this therapeutic pathway.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 22, 2026 to July 22, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/PancreaticCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Kuhlman and Ms Wagner have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Philip is on advisory committees with Corcept Therapeutics Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, and Revolution Medicines Inc; has consulting agreements with Novocure Inc; has contracted research with Bristol Myers Squibb, Novartis, Revolution Medicines Inc, and Taiho Oncology Inc; and is on data and safety monitoring boards/committees for J-Pharma Co Ltd and Oncolytics Biotech Inc.

MODERATOR — Dr O’Reilly is on advisory committees and has consulting agreements (uncompensated) with Agenus Inc, Alligator Bioscience, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Ikena Oncology, Immuneering Corporation, Ipsen Biopharmaceuticals Inc, Merck, MOMA Therapeutics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, and Tango Therapeutics; has contracted research with Agenus Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Revolution Medicines Inc, and Tango Therapeutics; and has nonrelevant financial relationships with American Association of Cancer Research (Editor), American Society of Clinical Oncology (Editor), Break Through Cancer, Imedex, National Cancer Institute (Cancer Center Support Grant/Core Grant), National Institutes of Health (research grant), and Stand Up 2 Cancer.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Ipsen Biopharmaceuticals Inc and Revolution Medicines Inc.

Release date: July 22, 2026
Expiration date: July 22, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Ahn DH et al. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: A retrospective analysis. Ther Adv Med Oncol 2017;9(2):75-82. Abstract

Anadkat MJ et al. Expert guidance on prophylaxis and treatment of dermatologic adverse events with tumor treating fields (TTFields) therapy in the thoracic region. Front Oncol 2023;12. Abstract

Babiker HM et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: Randomized, open-label, pivotal phase III PANOVA-3 Study. J Clin Oncol 2025;43(21):2350-60. Abstract

Ben-Aharon I et al. Early-onset cancer in the gastrointestinal tract is on the rise—Evidence and implications. Cancer Discov 2023;13(3):538-51. Abstract

Conroy T et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379(25):2395-406. Abstract

Gyawali B et al. WBC growth factors: ASCO guideline update. J Clin Oncol 2026;44(9):812-24. Abstract

Harrold E et al. Early-onset GI cancers: Rising trends, genetic risks, novel strategies, and special considerations. Am Soc Clin Oncol Educ Book 2023;43:e398068. Abstract

Hesketh PJ et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020;38(24):2782-97. Abstract

O’Reilly EM et al. Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC). AACR 2026;Abstract LB337.

Singhal A et al. Targeting KRAS in cancer. Nat Med 2024;30(4):969-83. Abstract

Stadler ZK et al. Therapeutic implications of germline testing in patients with advanced cancers. J Clin Oncol 2021;39(24):2698-709. Abstract

Wainberg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272-81. Abstract

Wainberg ZA et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Gastrointestinal Cancers Symposium 2023;Abstract LBA661.

Wolpin BM et al. Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC). AACR 2026;Abstract LB407.

Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol 2024;17(1):108. Abstract